According to FMI, the market for hyperinsulinemia hypoglycemia treatment is foreseen to rise to USD 100 million in FY 2023, representing a Y-o-Y increase of over 4%. Across the forecast period ranging from 2023 to 2033, the industry is likely to gain traction at a CAGR of 6%, reaching a market value of USD 179.08 million in FY 2033.
Maintaining normoglycemia is essential to prevent neurologic sequelae. Infants with hyperinsulinism are at higher risk of neurologic sequelae than infants with hypoglycemia from other causes. Because insulin inhibits lipolysis and ketogenesis, hyperinsulinism results in the paucity of alternative fuel used by the brain. The glucose output from the liver is 2-3 mg/kg/min in adults. Infants and children have a greater need for glucose and have a maximal output estimated at 5-7 mg/kg/min.
Owing to the increasing incidence of this disease, the market is anticipated to double over the next five years period at a compound annual growth Rate (CAGR) of 4.8%. The launches of the novel formulations of glucagon therapeutics will be the main drivers of market growth, with the first liquid-stable glucagons expected to launch during the forecast period in addition to increased uptake of the nasal glucagon Baqsimi. Other major drivers for the hypoglycemia market include the increased prevalence of type 1 diabetes (T1D) diagnoses, and the uptake of novel glucagon formulations will drive therapy usage over hospital treatment.
The primary unmet need, and the main opportunity in the space, is that there are no adequate treatments for non-diabetic hypoglycemia. These include but are not limited to, treatments for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (CHI). Other unmet needs for diabetic hypoglycemia include the lack of affordable treatments, the lack of convenient treatments, and the prevalence of hypoglycemia unawareness. The future level of attainment of these unmet needs will be medium-high, and there is not much of an opportunity for drug developers to enter the severe hypoglycemia market, but there is an opportunity to address the non-diabetic hypoglycemia market.
While there is a limited market for novel severe hypoglycemia treatments, physicians are primarily concerned with severe hypoglycemia prevention. The increasing trend of glucose monitoring in the treatment and management of insulin-dependent diabetic patients will impact the therapeutics that find success in the market. Increased monitoring will allow patients to catch hypoglycemia before it becomes severe. For T1D, the drive toward closed-loop pump systems, like an artificial pancreas, provides an opportunity for dual-hormonal pumps to use glucagon to actively manage hypoglycemia.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value for Hyperinsulinemia Hypoglycaemia Treatment in 2023 | USD 100 million |
| Expected Market Value for Hyperinsulinemia Hypoglycaemia Treatment in 2033 | USD 179.08 million |
| Growth rate (2023 to 2033) | 6% |
| Forecast period | 2023 to 2033 |
Explore FMI!
Book a free demo
According to FMI, the market for hyperinsulinemia hypoglycemia has reflected a value of 4% during the forecast period 2018 to 2022. Both PBH and CHI patients are rarely treated with glucagon due to the specific etiologies of their disease, and there are currently no targeted therapies approved for either indication.
Current treatment of CHI has not progressed from diazoxide and SSRAs used over the past two decades. Both medications are complicated by inefficacy and side effects, some of a life-threatening nature. The experimental therapy has not shifted the burden of drug-unresponsive CHI safely beyond subtotal pancreatectomy to justify routine clinical use. There is an urgent need to design new therapy to reduce insulin secretion and/or insulin action while maintaining normoglycaemia safely.
The development of chaperones that assist the trafficking of KATP channel components from the endoplasmic reticulum to the cell membrane is potentially an exciting area of drug development. KATP channels are analogous in structure to the cystic fibrosis transmembrane conductance regulator, CFTR.
Gene defects in CFTR are associated with cystic fibrosis through altered protein trafficking, similar to CHI. The corrector–potentiator combination of lumacaftor-ivacaftor is beneficial in cystic fibrosis 50; similar strategies could be used to improve the trafficking of KATP channels to improve channel function, although only limited effects of enhanced protein trafficking can be shown in isolated human CHI islets.
The increase in the prevalence of hyperinsulinemia hypoglycemia is one of the biggest drivers in the market. This condition is said to be more common in certain populations affecting 1 in 3000 newborns, where 60% of the babies with HI are diagnosed with hyperinsulinemia hypoglycemia in the first month itself. An additional 30% get diagnosed in the first year and the remainder after that. With early treatment and aggressive prevention of hypoglycemia, brain damage can be prevented.
The massive growth in the diabetic population is also primarily attributable due to the rising hyperinsulinemia hypoglycemia rates all around the globe, as well as the sedentary lifestyles led due to poor diets and a decrease in physical exercise.
Also, a strong relationship between diabetes and hyperinsulinemia hypoglycemia has been proven by certain studies. NCBI has stated that beta cell failure in type 2 diabetes (T2D) is associated with hyperglycemia, but the mechanisms are not fully understood, rather caused by glucokinase mutations (GCK-CHI) associated with beta cell replication and apoptosis that further shows that the genetic activation of beta cell glucokinase, triggers the replication caused by apoptosis that is associated with DNA double-strand breaks and activation of the tumor suppressor p53.
According to FMI, North America is assumed to acquire a market share of 25% in the forecast period. This growth is attributable to the rise in the prevalence of the condition in the region. Also, due to the presence of the leading technologies, the advancements in the healthcare sector, and the healthcare facilities with the improvement in technology, efficient treatments are being used.
The Asia-Pacific is anticipated to exhibit significant growth in all the regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed due to the increased awareness, significant increase in healthcare spending, and the rise in frequency of hyperinsulinemia hypoglycemia treatment in this particular region.
Asia-pacific is considered to be an emerging market due to the increase in the point care approach in health & care. Thus, the increasing number of hospitals in India and China makes it a promising market for the treatment market worldwide.
Nesidioblastosis is the most sought-after segment in this market
The majority of cases of adult-onset nesidioblastosis occurred after Roux-en-Y gastric bypass surgery and potential implicated mechanisms include increased levels of incretins (glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide); improved β-cell sensitivity to GLP-1; absence of post-surgery reduction of islet cell mass/function; increased insulin sensitivity secondary to weight loss; inappropriate insulin hypersecretion and anomalous counter-regulatory hormonal response to hypoglycemia.
Nesidioblastosis is a possible cause of HH in individuals without previous history of bariatric surgery and negative localizing imaging studies. In this condition hypoglycemia usually arises in the postprandial period. Treatment of nesidioblastosis includes the acute management of hypoglycemia and surgical or chronic medical treatment. Surgical treatment is the choice in patients with severe or refractory hypoglycemia. Before surgery, selective arterial calcium stimulation (SACST) should be done to determine whether the increased insulin secretion is focal or diffuse.
Business models evolve with time, sometimes due to changes in the market and sometimes due to the advent of technology, resulting in the emergence of new exciting trends. We at Tracxn closely track the startup ecosystem from across the world and we have come across a whole lot of interesting new themes which are gaining popularity, one of them being Diabetes Drugs.
The publisher performs competitive and market Intelligence analysis of the Vascular Dementia (VaD) market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Developments- The growth share matrix was built on the logic that market leadership results in sustainable superior returns. Ultimately, the market leader obtains a self-reinforcing cost advantage that competitors find difficult to replicate. These high growth rates then signal which markets have the most growth potential. The matrix reveals two factors that companies should consider when deciding where to invest—company competitiveness, and market attractiveness—with relative market share and growth rate as the underlying drivers of these factors.
Restrictions
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 100 million |
| Market Value in 2033 | USD 179.08 million |
| Growth Rate | 6% |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Type, Treatment, End User, Region |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | BCG Matrix; PESTLE Analysis; SWOT Analysis; Porter’s five forces; Market Entry Strategies, Inc.; Eisai Inc.; Eli Lilly; Novo Nordisk; Novartis AG; Xeris pharmaceuticals; Hanmi Pharmaceutical Co. Ltd. |
| Report Customization & Pricing | Available upon Request |
The hyperinsulinemia hypoglycemia treatment market is anticipated to go up from USD 100 million in 2023 to USD 179.08 million by 2033, exhibiting a CAGR of 6%.
The hyperinsulinemia hypoglycemia treatment market recorded a 4% CAGR between 2018 and 2022.
North America commands the prime share in the hyperinsulinemia hypoglycemia treatment market, driven by advanced healthcare infrastructure.
Integrated continuous glucose monitoring and novel drug developments are prevailing trends shaping the hyperinsulinemia hypoglycemia treatment market landscape.
Prominent market players such as BCG Matrix, Eisai Inc., Eli Lilly, Novo Nordisk, and Novartis AG dominate the hyperinsulinemia hypoglycemia treatment market.
Home Respiratory Therapy Market – Growth & Forecast 2025 to 2035
Veterinary Auto-Immune Therapeutics Market Growth - Trends & Forecast 2025 to 2035
Radial Compression Devices Market Growth - Trends & Forecast 2025 to 2035
Digital Telepathology Market is segmented by Application and End User from 2025 to 2035
Suture Anchor Devices Market Is Segmented by Product Type, Material Type, Tying and End User from 2025 to 2035
Home Infusion Therapy Devices Market - Growth & Forecast 2025 to 2035
Hyperinsulinemia Hypoglycaemia Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
